Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | PGK1 | P00558 | 2/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12146478 | 0.82 | ATR (0.35) | NUDT1ATRCCR4HTTKMT2A | |
| SCHEMBL15003295 | 0.78 | PGK1 (0.45) | PDE10APGK1EDNRACCR4KDM4E | |
| SCHEMBL7322176 | 0.78 | ADORA2A (0.37) | EDNRAATRCCR4HTTKMT2A | |
| SCHEMBL30588876 | 0.78 | ADORA2A (0.37) | EDNRAATRCCR4HTTKMT2A | |
| SCHEMBL6825411 | 0.78 | PDE10A (0.46) | PDE10AMAPKAPK2HTT | |
| SCHEMBL3018852 | 0.77 | CRHR1 (0.38) | ATRCCR4 | |
| SCHEMBL20387726 | 0.77 | ALDH1A1 (0.44) | ATRKDM4EL3MBTL1HTTKMT2A | |
| SCHEMBL15803560 | 0.75 | ATR (0.38) | EDNRAATRCCR4HTTKMT2A | |
| SCHEMBL20607670 | 0.74 | TLR8 (0.47) | EDNRAATRCCR4KMT2A | |
| SCHEMBL21388100 | 0.74 | ADORA3 (0.35) | ATRCCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245611-B | mTOR kinase inhibitors for use in mTOR/PI 3K/AKT/pathway-related oncology indications and diseases | 西格诺药品有限公司 | 2016-10-26 | — | — | CN | disclosed |